<DOC>
	<DOCNO>NCT00000878</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerance 2 anti-HIV drug , d4T 3TC , give combination HIV-positive pregnant woman infant . Most HIV-positive pregnant woman usually take anti-HIV drug zidovudine ( ZDV ) treat HIV reduce chance give HIV baby . It recently show combination drug may effective ZDV alone . This study test effectiveness combination ZDV , d4T , 3TC .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerance Stavudine ( d4T ) Combination With Lamivudine ( 3TC ) HIV-Positive Pregnant Women Their Infants</brief_title>
	<detailed_description>New antiretroviral agent combination seek efficacious ZDV would effective reduce rate vertical transmission HIV woman long-term recipient ZDV . d4T good candidate drug . It thymidine nucleoside analogue inhibits replication HIV concentration similar ZDV anti-HIV activity . The demonstrated safety profile d4T , ease administration , , importantly , preliminary efficacy data , especially combination 3TC , make excellent candidate combination Phase I perinatal trial . Two cohort woman infant enrol study . The first five mother/infant pair enrol comprise Group I . Mothers enrol group must allow infant receive ZDV . Eight mother/infant pair enrol Group II ; Group II infant allocate two group : whose mother allow administration ZDV ( Group IIA ) whose mother ( Group IIB ) . Group I : Women : Beginning minimum 14 week gestation : 1 . Oral d4T start active labor . 2 . Oral 3TC . At start active labor ( defined regular uterine contraction result cervical dilation [ 3-4 cm ] effacement [ 50-60 % ] ) delivery : 1. d4T administer IV load dose follow continuous infusion umbilical cord clamp . 2 . Oral 3TC patient 's previous dose 3TC administer least 0.5h prior onset labor additional dose 3TC administered time next dose schedule accordingly . Infants : 1. d4T single oral dose Day 6 ( +/- 2 day ) Day 42 ( dose give Days 35 42 , inclusive ) . 2 . Oral ZDV ( IV unable take oral dose ) 6 week , begin maximum 12 hour birth . 3 . 3TC 6 week , begin maximum 12 hour birth . Group II : Women : Beginning minimum 14 week gestation : 1 . Oral d4T umbilical cord clamp . 2 . Oral 3TC . At start active labor delivery : Oral d4T 3TC . If last dos d4T 3TC give least 0.5 hour prior onset active labor , additional dose d4T 3TC give repeat every 12 hour . Infant Group IIA : 1. d4T single oral dose Day 6 ( +/- 2 day ) Day 42 ( dose give Days 35 42 , inclusive ) . 2 . Oral ZDV ( IV unable tolerate oral dosing ) 6 week , begin maximum 12 hour birth . 3 . 3TC 6 week , begin maximum 12 hour birth . Infant Group IIB : Beginning maximum 12 hour birth : 1. d4T 6 week . 2 . 3TC 6 week . [ AS PER AMENDMENT 9/15/97 : If tolerate , infant continue protocol treatment 6 week age . At 6 week , infant receive standard care , include PCP prophylaxis , HIV specialist/pediatrician . HIV-infected infant offer ACTG trial enrollment open-label treatment base best clinical judgment physician . ] [ AS PER AMENDMENT 2/19/99 : Patients prematurely discontinue study treatment continue follow study duration study . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Women may eligible study : Are HIVpositive . Are least 13 year old ( need consent parent guardian 18 ) . Are unable refuse take ZDV woman 's doctor say take d4T . Are 14 34 week pregnant . Exclusion Criteria Women eligible study : Have history peripheral neuropathy . Have active opportunistic infection and/or serious bacterial infection within 14 day study entry . Have severe diarrhea . Are allergic d4T 3TC . Use illicit drug abuse alcohol . Are take antiHIV drug study medication . Are plan breastfeed . Are problem pregnancy ( baby develop correctly survive birth ) pregnancy complication past . Babies eligible study : Are unable take medication mouth 72 hour . Have severe birth defect lifethreatening condition . Are underweight ( less 2 kg ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>